Subscribe
handshake-istock-512549722-choreograph-
Choreograph / iStockphoto.com
5 January 2018Americas

Stanford University enters licence agreement for EGF technology

Stanford University has entered into a licensing agreement with Madenco Biosciences to develop and commercialise patented epidermal growth factor (EGF) wound healing technology.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Tribal business settles Stanford opioid treatment clash
29 November 2022   Dispute centred on patented data to treat opioid addiction | Tribe said it had shared confidential data to develop a cure | Stanford University.
Americas
Fed Circuit rejects Stanford Uni’s ‘abstract’ genetics patent
15 March 2021   Stanford University can’t patent a genetic testing method as it is based on “abstract mathematical calculations”, the US Court of Appeals for the Federal Circuit has ruled.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Americas
Tribal business settles Stanford opioid treatment clash
29 November 2022   Dispute centred on patented data to treat opioid addiction | Tribe said it had shared confidential data to develop a cure | Stanford University.
Americas
Fed Circuit rejects Stanford Uni’s ‘abstract’ genetics patent
15 March 2021   Stanford University can’t patent a genetic testing method as it is based on “abstract mathematical calculations”, the US Court of Appeals for the Federal Circuit has ruled.

More on this story

Americas
Tribal business settles Stanford opioid treatment clash
29 November 2022   Dispute centred on patented data to treat opioid addiction | Tribe said it had shared confidential data to develop a cure | Stanford University.
Americas
Fed Circuit rejects Stanford Uni’s ‘abstract’ genetics patent
15 March 2021   Stanford University can’t patent a genetic testing method as it is based on “abstract mathematical calculations”, the US Court of Appeals for the Federal Circuit has ruled.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB